Anti-Human Angiopoietin-like Protein 3/ANGPTL3 Reference Antibody (Evinacumab, RUO) (HV176016)

Name: Anti-Human Angiopoietin-like Protein 3/ANGPTL3 Reference Antibody (Evinacumab, RUO)
Brand: abinScience
SKU: HV176016
Price: 176 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo	HV176016
Descripción	Evinacumab (HV176016) is a research-grade recombinant antibody targeting ANG-5. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactividad de especies	Human
Aplicaciones	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Especie huésped	Human
Clonalidad	Monoclonal
Isotipo	IgG4-kappa
Sistema de expresión	Mammalian cells
Objetivo	ANG-5, Angiopoietin-like protein 3, ANGPT5, Angiopoietin-5, ANGPTL3, Angiopoietin-related protein 3
Nivel de endotoxinas	< 10 EU/mg
Pureza	>95% purity as determined by SDS-PAGE.
Purificación	Protein A/G purified from cell culture supernatant.
Número de acceso	Q9Y5C1
Forma	Liquid
Buffer de almacenamiento	0.01M PBS pH 7.4 Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Estabilidad y almacenamiento	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativos	REGN1500, 1446419-85-7
Fondo	Angiopoietin-related protein 3 (ANGPTL3) is a ~53 kDa protein. Acts in part as a hepatokine that is involved in regulation of lipid and glucose metabolism. Proposed to play a role in the trafficking of energy substrates to either storage or oxidative tissues in response to food intake. Has a stimulatory effect on plasma triglycerides (TG), which is achieved by suppressing plasma TG clearance via inhibition of LPL activity. The inhibition of LPL activity appears to be an indirect mechanism involving recruitment of proprotein convertases PCSK6 and FURIN to LPL leading to cleavage and dissociation of LPL from the cell surface; the function does not require ANGPTL3 proteolytic cleavage but seems to be mediated by the N-terminal domain, and is not inhibited by GPIHBP1. Can inhibit endothelial lipase, causing increased plasma levels of high density lipoprotein (HDL) cholesterol and phospholipids. 1. Koishi, R. et al. (2002) Nature genetics 30, 151-7. PMID: 11788823 2. Ono, M. et al. (2003) The Journal of biological chemistry 278, 41804-9. PMID: 12909640 3. Robciuc, MR. et al. (2013) Arteriosclerosis, thrombosis, and vascular biology 33, 1706-13. PMID: 23661675 4. Tikka, A. et al. (2014) Bioscience reports 34, e00160. PMID: 25495645 5. Shimizugawa, T. et al. (2002) The Journal of biological chemistry 277, 33742-8. PMID: 12097324 6. Lee, EC. et al. (2009) The Journal of biological chemistry 284, 13735-13745. PMID: 19318355 7. Liu, J. et al. (2010) The Journal of biological chemistry 285, 27561-70. PMID: 20581395 8. Shimamura, M. et al. (2007) Arteriosclerosis, thrombosis, and vascular biology 27, 366-72. PMID: 17110602 9. Shan, L. et al. (2009) The Journal of biological chemistry 284, 1419-24. PMID: 19028676 10. Shimamura, M. et al. (2003) Biochemical and biophysical research communications 301, 604-9. PMID: 12565906
Nota	For research use only. Not suitable for clinical or therapeutic use.
Isotype Control	Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507)